文献速递其他结缔组织病血管炎

赖氨酰氧化酶在系统性硬化症相关肺动脉高压中的可能作用:多中心研究

Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

该多中心研究比较了86例确诊SSc患者与86例极早期SSc(VEDOSS)、110例原发性雷诺现象(PRP)及80例健康对照的血清LOX水平,发现SSc患者LOX显著升高且与DLCO负相关,中重度肺动脉高压患者LOX更高,肺活检显示LOX主要位于重塑肺血管内皮。

要点

  • 确诊SSc患者血清LOX水平显著高于VEDOSS、PRP和健康对照(P<0.001)。
  • 弥漫性SSc中LOX与DLCO呈负相关(r=-0.376,P=0.02)。
  • 中重度估测肺动脉高压患者LOX水平更高(P<0.01),肺活检示LOX位于重塑肺血管内皮。

核心结论

  • 血清LOX在确诊SSc中升高并与DLCO负相关,在中重度肺动脉高压患者中升高且位于肺小动脉增殖内皮,提示LOX可能参与SSc相关肺动脉高压。

研究设计与样本

  • 多中心研究,纳入86例确诊SSc患者、86例VEDOSS、110例PRP患者和80例健康对照,用ELISA检测血清LOX,并对5例肺和12例皮肤活检进行LOX染色并与对照比较。

主要发现

  • SSc患者血清LOX显著高于VEDOSS、PRP和健康对照(P<0.001)。
  • 弥漫性SSc中LOX与DLCO呈负相关(r=-0.376,P=0.02)。
  • 中重度估测收缩期肺动脉高压患者LOX水平更高(P<0.01)。
  • 肺活检显示伴肺动脉高压的SSc患者LOX强染色,主要位于重塑肺血管内皮。

临床怎么用

  • 在确诊SSc患者中可关注血清LOX水平,其与DLCO负相关及与中重度肺动脉高压的关联提示LOX可能作为SSc相关肺动脉高压的潜在生物标志物。

局限性

  • 肺活检样本量小(5例肺和12例皮肤),未报告诊断或分类标准细节,无法确定LOX与肺动脉高压的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Lysyl oxidase (LOX) is an extracellular enzyme that cross-links collagen fibrils. LOX was found to be increased in serum of SSc patients and was suggested to be related to skin fibrosis, yet a vascular source of LOX has been demonstrated in idiopathic pulmonary arterial hypertension (iPAH). We aimed to validate elevated LOX serum levels in SSc and to study its correlation with clinical characteristics and investigate its main source at the tissue level. METHODS: A total of 86 established SSc patients were compared with 86 patients with very early diagnosis of systemic sclerosis (VEDOSS), 110 patients with primary RP (PRP) and 80 healthy controls. LOX serum levels were determined by ELISA. Five lung and 12 skin biopsies from SSc patients were stained for LOX and compared with controls. RESULTS: Serum levels of LOX in SSc were significantly higher than in VEDOSS, PRP and healthy controls (P < 0.001). LOX inversely correlated with the diffusing capacity of the lung for carbon monoxide diffusing capacity (DLCO) in diffuse SSc (r = -0.376, P = 0.02). Patients with moderate to severe estimated systolic PAH had higher LOX levels (P < 0.01). Lung biopsies demonstrated intense LOX staining in SSc patients with PAH that was predominantly located in the endothelium of the remodelled pulmonary vessels. CONCLUSION: Serum LOX levels are increased in established SSc and inversely correlate with the DLCO. LOX is elevated in patients with moderate to severe PAH and is located in the proliferating endothelium in lung arterioles, suggesting a possible role for LOX in SSc-associated PAH.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Vadasz Z, Balbir Gurman A, Meroni P, et al. Lysyl oxidase-a possible role in systemic sclerosis-associated pulmonary hypertension: a multicentre study. Rheumatology (Oxford). 2019. PMID: 30770717. doi:10.1093/rheumatology/kez035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。